Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

563.16
+13.882.53%
Post-market: 563.160.00000.00%19:42 EDT
Volume:827.81K
Turnover:462.63M
Market Cap:60.27B
PE:14.69
High:564.21
Open:548.07
Low:545.00
Close:549.28
Loading ...

Odronextamab Bla Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma

THOMSON REUTERS
·
26 Feb

Regeneron Pharmaceuticals Inc - FDA Decision on Odronextamab Expected by July 30, 2025

THOMSON REUTERS
·
26 Feb

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma

GlobeNewswire
·
26 Feb

Regeneron Pharmaceuticals, Inc. (REGN): Among the Stocks That Will Go to The Moon According to Analysts

Insider Monkey
·
26 Feb

Regeneron Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

Dow Jones
·
25 Feb

Regeneron announces updated DB-OTO data from CHORD trial

TIPRANKS
·
25 Feb

BRIEF-Regeneron's DB-OTO Results Show Hearing Improvements In Children With Profound Genetic Hearing Loss

Reuters
·
25 Feb

Regeneron's gene therapy study shows improved hearing in children with congenital deafness

Reuters
·
25 Feb

Regeneron: 72-Week Results for Db-Oto Shows Speech and Development Progress in First Child Dosed at 10 Months of Age

THOMSON REUTERS
·
25 Feb

Regeneron: 10 of 11 Children With at Least One Post-Treatment Assessment Showed Notable Improvements in Hearing in Phase 1/2 Chord Trial

THOMSON REUTERS
·
25 Feb

Regeneron: Db-Oto Results Show Clinically Meaningful Hearing Improvements in Nearly All Children With Profound Genetic Hearing Loss in Chord Trial

THOMSON REUTERS
·
25 Feb

Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial

GlobeNewswire
·
25 Feb

Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts

Insider Monkey
·
25 Feb

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2025-02-24

Reuters
·
25 Feb

The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis

Zacks
·
24 Feb

Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More

Zacks
·
21 Feb

2 Healthcare Stocks with Big Upside and 1 to Skip

StockStory
·
21 Feb

US must meet tougher standard in Regeneron kickback lawsuit

Reuters
·
19 Feb

FOCUS-Next generation weight loss drugs aim to save muscle

Reuters
·
19 Feb

Alvotech, Teva Pharmaceutical's Bionsimlar Eye Disorder Potential Treatment Accepted for FDA Review

MT Newswires Live
·
18 Feb